Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Clinical trial NCT02122861 · COMPLETED

Trial details

NCT number: NCT02122861
Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma - Currently Enrolling Non-small Cell Lung Cancer - Enrollment Completed Sarcoma - Enrollment Completed

Start date: 2014-05-30
Primary completion: 2018-11-14
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.